z-logo
open-access-imgOpen Access
Evaluating Risks for Vigabatrin Treatment
Author(s) -
Krauss Gregory L.
Publication year - 2009
Publication title -
epilepsy currents
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 22
eISSN - 1535-7511
pISSN - 1535-7597
DOI - 10.1111/j.1535-7511.2009.01315.x
Subject(s) - vigabatrin , medicine , asymptomatic , epilepsy , pediatrics , anesthesia , surgery , psychiatry , anticonvulsant
Approximately 30 to 40 percent of adults with epilepsy treated chronically with vigabatrin develop concentric visual field constrictions. These deficits are generally mild and asymptomatic, but are usually irreversible, so risks and benefits for vigabatrin treatment must be carefully reviewed. Infantile spasms, a particularly severe form of epilepsy, may respond to vigabatrin; however, some infants treated with the drug develop MRI evidence of possible intramyelinic edema in subcortical structures. This article reviews the benefits of vigabatrin treatment, the risks it poses to the retina and the developing brain, as well as possible subgroups of adults and infants with severe epilepsy for whom treatment may, nevertheless, be warranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here